5 Apr 2018
Dr Jan Petracek

Dr. Jan Petracek was appointed to the Board as Chief Operating Officer in December 2017 and has been Chief Executive Officer of PrimeVigilance since April 2017. He joined the Ergomed group in November 2016 following the acquisition of European PharmInvent Services s.r.o., where he was founder and CEO. Dr. Petracek is the former Head of Risk Management at the European Medicines Agency and the former Head of Pharmacovigilance, Strategy and Development at the State Institute for Drug Control in the Czech Republic. Dr. Petracek was the EU Qualified Person responsible for pharmacovigilance at Vertex Pharmaceuticals, Biogen and BluePrint Medicines.

Dr. Petracek studied Quality and Safety in Healthcare (MSc) at Imperial College London and trained as a physician at Charles University in Prague (MD).

Dr. Petracek sits on the Advisory Board of the International Society of Pharmacovigilance and is a regular speaker at international pharmacovigilance conferences and training seminars.

Dr. Petracek keeps his skillset up-to-date by attending pharmacovigilance conferences and courses, and attending leadership coaching and business mentoring sessions.

As the founder of several successful organisations, Dr. Petracek brings entrepreneurship, business acumen and a track record of innovation in pharmacovigilance to the Board. As a senior ex-regulator, he has a deep understanding of the pharmaceutical regulatory environment.